Eyeing big therapeutic push, Ginkgo bags $290M to build a cell programming empire

Amber Tong

Senior Editor

Ginkgo Bioworks is on a roll. Days after publicizing a plan to nurture new startups via partnerships with accelerators Y Combinator and Petri, the Boston biotech says it has raised another $290 million for its cell programming platform to reach further and wider.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Eyeing big therapeutic push, Ginkgo bags $290M to build a cell programming empire

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

Merck KGaA’s evobrutinib disappoints in PhIII multiple sclerosis test, casting dark cloud over BTK class

J&J notebook: Highlights from a day of pipeline and strategy discussion

Will the UK’s triple-pronged approach ease pricing, regulatory and financial bottlenecks?

FDA sends letter to Novartis over 'significant' Kymriah manufacturing safety concerns

IGM Biosciences cuts 22% of workforce, axes hematologic oncology program

Early prediction of outcomes in DLBCL clinical trials through MRD testing

Eye­ing big ther­a­peu­tic push, Gink­go bags $290M to build a cell pro­gram­ming em­pire

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

Mer­ck KGaA’s evo­bru­ti­nib dis­ap­points in PhI­II mul­ti­ple scle­ro­sis test, cast­ing dark cloud over BTK class

J&J note­book: High­lights from a day of pipeline and strat­e­gy dis­cus­sion

Will the UK’s triple-pronged ap­proach ease pric­ing, reg­u­la­to­ry and fi­nan­cial bot­tle­necks?

FDA sends let­ter to No­var­tis over 'sig­nif­i­can­t' Kym­ri­ah man­u­fac­tur­ing safe­ty con­cerns

IGM Bio­sciences cuts 22% of work­force, ax­es hema­to­log­ic on­col­o­gy pro­gram

Ear­ly pre­dic­tion of out­comes in DL­B­CL clin­i­cal tri­als through MRD test­ing

Eyeing big therapeutic push, Ginkgo bags $290M to build a cell programming empire

Merck KGaA’s evobrutinib disappoints in PhIII multiple sclerosis test, casting dark cloud over BTK class

J&J notebook: Highlights from a day of pipeline and strategy discussion

Will the UK’s triple-pronged approach ease pricing, regulatory and financial bottlenecks?

FDA sends letter to Novartis over 'significant' Kymriah manufacturing safety concerns

IGM Biosciences cuts 22% of workforce, axes hematologic oncology program

Early prediction of outcomes in DLBCL clinical trials through MRD testing